|Alefacept (Code C65220)|
|Terms & Properties|
Preferred Name: Alefacept
Definition: A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3; CD58) linked to the Fc portion of human immunoglobulin G1 (IgG1) with potential immunosuppressive activity. Alefacept binds to the CD2 receptor expressed on the majority of T lymphocytes, blocking the binding of endogenous LFA-3, located on antigen-presenting cells (APCs), to the CD2 receptor; the activation and proliferation of T lymphocytes in response to LFA-3 binding is thus inhibited. In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes.
NCI-GLOSS Definition: A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Alefacept is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant.
Display Name: Alefacept
NCI Metathesaurus Link: C0962603 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||222535-22-0 (see NLM ChemIDplus info)|
|FDA UNII Code||ELK3V90G6C|
|PDQ Closed Trial Search ID||531798|
|PDQ Open Trial Search ID||531798 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|